Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet-Reference-Cited by-同舟云学术

Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet

Published:2016-01-15 Issue:7 Volume:18 Page:702-706
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Nishimura R.¹,Omiya H.²,Sugio K.²,Ubukata M.²,Sakai S.²,Samukawa Y.²

Affiliation:

1. Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine Jikei University School of Medicine Tokyo Japan

2. Taisho Pharmaceutical Co., Ltd. Tokyo Japan

Funder

Taisho Pharmaceutical Co., Ltd

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12611

Reference11 articles.

1. Luseogliflozin: First Global Approval

2. Luseogliflozin for the treatment of type 2 diabetes

3. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

4. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study

5. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal, cardiovascular, and safety outcomes of adding sodium–glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis;International Urology and Nephrology;2023-07-29

2. Low-carbohydrate diet in the treatment of type 2 diabetes mellitus (LoCaT): study protocol for a multicenter, randomized controlled trial;Trials;2023-06-19

3. Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-03

4. Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet;Cureus;2022-10-17

5. Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes;Endocrine Journal;2022